Clodronic acid disodium salt
Based on 5 publication(s) in Google Scholar
Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Assay : 100.50%
- CAS No.: 22560-50-5
- Formule: CH2Cl2Na2O6P2
- Masse moléculaire:288.86
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Clodronic acid disodium salt
More
Activité biologique
Description
In Vitro
Clodronic acid disodium salt induces rapid apoptosis in osteoclasts by preventing translocation of ADP into mitochondria after being internalised via resorption. Consequently, ATP production is inhibited, leading to induction of apoptosis by means of release of cytochrome C into the cytoplasm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Lewis rats, aged 7 weeks[3]
-
Dosage:6.25, 12.5, and 25 mg/kg
-
Administration:P.o.; daily for 28 days
-
Result:Hindpaw swelling was significantly smaller than in adjuvant-arthritis (AA)-control at 25 mg/kg on days 21 and 28 (87 and 88% of AA-control, respectively) and at 12.5 mg/kg on day 28.
Chemical Information
-
CAS No. 22560-50-5
-
Appearance Solid
-
Masse moléculaire 288.86
-
Formule CH2Cl2Na2O6P2
-
Color White to off-white
-
SMILES
O=P(C(Cl)(Cl)P(O)(O[Na])=O)(O)O[Na]
-
Synonyms
Clodronate disodium salt
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Neurosci
Spatiotemporally selective astrocytic ATP dynamics encode injury information sensed by microglia following brain injury in mice. [Abstract]2024 Aug;27(8):1522-1533. PMID: 38862791 -
ACS Nano
Localized Depletion of Macrophages by Abdominal Cavity Retention Nanoparticles as a Potential Therapy for Peritoneal Metastasis. [Abstract]2026 Jun 16;20(23):16987-17000. PMID: 42225301 -
J Adv Res
Dual regulation of phaseol on osteoclast formation and osteoblast differentiation by targeting TAK1 kinase for osteoporosis treatment. [Abstract]2024 Dec 9:S2090-1232(24)00565-4. PMID: 39662728 -
Phytomedicine
Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway. [Abstract]2025 Mar:138:156429. PMID: 39939034 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618
Solvant et solubilité
In Vitro:
H2O : 100 mg/mL (346.19 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (346.19 mM); Clear solution; Need ultrasonic
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Morgan GJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-1999. [Content Brief]
[2]. Tanakol R, et al. Clodronic acid in the treatment of postmenopausal osteoporosis. Clin Drug Investig. 2007;27(6):419‐433. [Content Brief]
[3]. Itoh F, et al. Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation. 2004 Feb;28(1):15-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.4619 mL | 17.3094 mL | 34.6188 mL | 86.5471 mL |
| 5 mM | 0.6924 mL | 3.4619 mL | 6.9238 mL | 17.3094 mL | |
| 10 mM | 0.3462 mL | 1.7309 mL | 3.4619 mL | 8.6547 mL | |
| 15 mM | 0.2308 mL | 1.1540 mL | 2.3079 mL | 5.7698 mL | |
| 20 mM | 0.1731 mL | 0.8655 mL | 1.7309 mL | 4.3274 mL | |
| 25 mM | 0.1385 mL | 0.6924 mL | 1.3848 mL | 3.4619 mL | |
| 30 mM | 0.1154 mL | 0.5770 mL | 1.1540 mL | 2.8849 mL | |
| 40 mM | 0.0865 mL | 0.4327 mL | 0.8655 mL | 2.1637 mL | |
| 50 mM | 0.0692 mL | 0.3462 mL | 0.6924 mL | 1.7309 mL | |
| 60 mM | 0.0577 mL | 0.2885 mL | 0.5770 mL | 1.4425 mL | |
| 80 mM | 0.0433 mL | 0.2164 mL | 0.4327 mL | 1.0818 mL | |
| 100 mM | 0.0346 mL | 0.1731 mL | 0.3462 mL | 0.8655 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Clodronic acid disodium salt Related Classifications
HY-B0657A Related Classifications
Powered by Bioz